Covid Vaccines Will Make People More Sick And No Peer Reviewed Studies Show That It Was Proven To Be Safe Or Effective
Letter to WV Legislators – The Moderna COVID-19 vaccine is likely to make more people sick than COVID-19
By: The Children’s Health Defense Team
On July 14, 2020 the New England Journal of Medicine published the preliminary report of the results from the phase 1 trials of Moderna’s vaccine for COVID-19. Despite an extremely high percentage of Moderate to Severe adverse events after the second dose, the group’s conclusion was that “no trial-limiting safety concerns were identified. These findings support further development of this vaccine.”
The following letter was written by the West Virginians for Health Freedom group and sent to all West Virginia’s legislators.
Dear Legislator,
The study “Informed Consent Disclosure to Vaccine Trial Subjects of Risk of COVID-19 Vaccine Worsening Clinical Disease,”
A new study examining how informed consent is given to the COVID vaccine trial participants found that disclosure forms were not sufficient for the participants to understand that the vaccine could make them more susceptible to worse disease later.
The study,1 “Informed Consent Disclosure to Vaccine Trial Subjects of Risk of COVID-19 Vaccine Worsening Clinical Disease,” published in the International Journal of Clinical Practice, October 28, 2020, points out that “COVID-19 vaccines designed to elicit neutralizing antibodies may sensitize vaccine recipients to more severe disease than if they were not vaccinated.”
· “Vaccines for SARS, MERS and RSV have never been approved, and the data generated in the development and testing of these vaccines suggest a serious mechanistic concern: that vaccines designed empirically using the traditional approach (consisting of the unmodified or minimally modified coronavirus viral spike to elicit neutralizing antibodies), be they composed of protein, viral vector, DNA or RNA and irrespective of delivery method, may worsen COVID-19 disease via antibody-dependent enhancement (ADE),” the paper states.
· “This risk is sufficiently obscured in clinical trial protocols and consent forms for ongoing COVID-19 vaccine trials that adequate patient comprehension of this risk is unlikely to occur, obviating truly informed consent by subjects in these trials.
· The specific and significant COVID-19 risk of ADE should have been and should be prominently and independently disclosed to research subjects currently in vaccine trials, as well as those being recruited for the trials and future patients after vaccine approval, in order to meet the medical ethics standard of patient comprehension for informed consent.”
https://onlinelibrary.wiley.com/doi/10.1111/ijcp.13795
What is ADE or Antibody-Dependent Enhancement?
According to International Journal of Clinical Practice paper, previous coronavirus vaccine efforts for SARS-CoV, MERS-CoV and RSV have revealed a serious concern: The vaccines have a possibility to trigger antibody-dependent enhancement.
What exactly does that mean? It means that vaccine, instead of enhancing your immunity against the infection, it encourages the cells to become infected with the agent, resulting in more severe disease than had you not been vaccinated.
This is exactly opposite of what vaccines are supposed to do and one of main concerns when it comes to Covid 19 vaccine.
The 2003 review paper “Antibody-Dependent Enhancement of Virus Infection and Disease” explains it this way:
· “In general, virus-specific antibodies are considered antiviral and play an important role in the control of virus infections in a number of ways. However, in some instances, the presence of specific antibodies can be beneficial to the virus. This activity is known as antibody-dependent enhancement (ADE) of virus infection.
· The ADE of virus infection is a phenomenon in which virus-specific antibodies enhance the entry of virus, and in some cases the replication of virus, into monocytes/macrophages and granulocytic cells through interaction with Fc and/or complement receptors.
· This phenomenon has been reported in vitro and in vivo for viruses representing numerous families and genera of public health and veterinary importance. These viruses share some common features such as preferential replication in macrophages, ability to establish persistence, and antigenic diversity. For some viruses, ADE of infection has become a great concern to disease control by vaccination.”
Previous Coronavirus Vaccine Efforts Have All Failed
In one of interviews with Robert Kennedy Jr., he summarized the history of coronavirus vaccine development, which began in 2002, following three consecutive SARS outbreaks. By 2012, Chinese, American, and European scientists were working on SARS vaccine development and had about 30 promising candidates.
Of those, the four best vaccine candidates were then given to ferrets, which are the closest analogue to human lung infections. While the ferrets displayed robust antibody response, which is the metric used for vaccine licensing, once they were challenged with the wild virus, they all became severely ill and died.
The same thing happened when they tried to develop an RSV vaccine in the 1960s. RSV is an upper respiratory illness that is very similar to that caused by coronaviruses. At that time, they had decided to skip animal trials and go directly to human trials.
“They tested it on I think about 35 children, and the same thing happened,” Kennedy said. “The children developed a champion antibody response — robust, durable. It looked perfect [but when] the children were exposed to the wild virus; they all became sick. Two of them died. They abandoned the vaccine. It was a big embarrassment to FDA and NIH.”
Covid-19 vaccines: where are the data?
On November 27, 2020 in the BMJ’s opinion (Comment and opinion from The BMJ's international community of readers, authors, and editors) following was released:
“Through press releases, three pharmaceutical companies recently announced the interim, positive results of their covid-19 vaccine candidates clinical trials. Firstly, Pfizer/BioNTech presented the initial results for their mRNA based BNT162b2 vaccine, which showed that it was 90% effective in preventing covid-19. [1] The vaccine was tested on 43,538 participants and, so far, there have been 94 confirmed cases. [2] They will submit to the US Food and Drug Administration (FDA) for approval when the safety profile has reached a pre-determined milestone. In the meantime, Pfizer has continued to market the vaccine.
Secondly, the Data Safety Monitoring Board, appointed by the National Institutes of Health (NIH) for the phase III study of the MODERNA mRNA-1273 vaccine candidate against covid-19, confirmed its trial met the statistical criteria pre-specified in the study protocol, with a vaccine efficacy of 94.5%. [3,4]
Thirdly, the University of Oxford and AstraZeneca, announced that their adenovirus-based vaccine ChAdOx1 nCoV-2019 was safe and also, in the preliminary findings of a peer-reviewed phase II/III trial, as triggering a seemingly encouraging immune response in older age groups included in the trial. [5] In a subsequent press release, they reported that in the phase III trial of about 20,000 participants, the vaccine was around 70% efficacious. This week it has also transpired that some of the participants were, in error, given a first dose which was half of what was intended. These participants were all under the age of 55. Doubts have now been raised about how Oxford and Astra Zeneca have handled the release of their preliminary results, given the dosing error and what that could mean for the efficacy of the vaccine.
All these data for the different vaccines are potentially very promising, but none of the phase III trials have been published in peer reviewed journals or analysed by age group, gender and case description (asymptomatic, mild, severe), virus transmissibility after immunisation, or duration of protection.
As public health professionals, we believe that the results of clinical trials, whether interim or final, should be subject to an appropriate systematic process, and then published in peer-reviewed professional journals. Reporting the covid-19 vaccine trial results in press releases before publication in journals is neither good scientific practice nor does it help to build public trust in vaccines. If trial data for covid-19 candidate vaccines are prematurely announced, this may threaten the integrity and credibility of the trials. This could distort what should be a rigorous peer review process. [7] We believe that data and conclusions should not be released as credible before the scientific community can judge the validity of those claims by assessing a complete account of what was done. [8]
The process of reporting on the clinical trials and the concurrent marketing of the covid-19 vaccines also raises concerns about the basis on which the many candidate vaccines at advanced stages of development can be assessed. Since companies are asking governments to place orders at an early stage, this raises a question about the minimum amount of data that companies should release publicly during the marketing process. [9]
It is crucial that the World Health Organisation, as a credible neutral body, should appoint a group of experts to compile an updated list of the current status of the clinical trials and to specify how to communicate the results. We believe that this should be within the WHO framework of The Access to COVID-19 Tools (ACT) Accelerator initiative. [10] This overview should identify all aspects of the vaccine production and the trial methodology. For example, production methods should specify all the ingredients including antigens, adjuvants, stabilisers, antibiotics and preservatives.
Companies should be encouraged to publish a paper with their trial design, methods and results in a peer-reviewed journal. And given that we should strive to publish these papers as rapidly as possible, journals should prioritise them, and ensure rigour and timeliness in their peer-review process.
The scientific publication should at least include the following:
· detailed study design
· method of recruiting participants
· sample size in total and by study arm.
· main characteristics of the study population including age, gender, ethnicity, health status and other key variables.
· detailed features of the vaccine
· storage requirements
· dose
· route of administration and schedule
· trial duration
· total accrual time
· loss to follow-up, as specified in the standard protocols for clinical trials investigating vaccines. [11]
Safety and efficacy evaluation should identify the primary and secondary endpoints. Results need to be presented systematically, with precise statistical analyses and specification of the overall efficacy and sub-group efficacy (with confidence intervals), and adverse effects analyses by age group and sex. The authors also need to discuss the strengths and limitations of the trial. [12] There are other relevant questions that the company should discuss, such as the possible impact of carrying out the trial in a limited time. In addition, the authors must present the current understanding of the following:
· estimates of how long after immunisation it takes to be protected
· the estimated duration of protection
· whether vaccination will prevent transmission
· to what extent violations of the cold-chain affect the efficacy of the vaccine
· could there be atypical disease in vaccinated subjects.
Governments, public health professionals and society as a whole must support fair and equitable access for every country. To help with the logistical and practical aspects of making this happen, all the information from the clinical trials must have incontrovertible credibility. [13] In summary, with covid-19 vaccines there are reasons to be hopeful, but we need to address the concerns. [14] We strongly advocate for the need to define a standard protocol on what data must be released before a company starts to market its vaccine. This should be complemented with guidelines on how to compare the benefits of each new vaccine as it becomes available. We believe the WHO is best suited to coordinate such a process.
Jose M Martin-Moreno is professor of preventive medicine and public health at the Medical School and INCLIVA-Clinical Hospital, University of Valencia, Spain, and Honours’ committee chair, Association of Schools of Public Health in the European region.
John Middleton is honorary professor of public health, Wolverhampton University, and president of the Association of Schools of Public Health in the European region.
Mohamud Sheek-Hussein is associate professor, Institute of Public Health, College of Medicine & Health Sciences, UAE University, Al-Ain, UAE.
Manfred S Green is professor of epidemiology and public health, and head of the International MPH Program, School of Public Health, University of Haifa, Israel.
Competing interests: None declared.”
https://blogs.bmj.com/bmj/2020/11/27/covid-19-vaccines-where-are-the-data/
Watch the video of Medical Professionals Globally Speaking Out About Danger Of New Covid19 Vaccine:
Sources:
https://childrenshealthdefense.org/
The above article (Letter to WV Legislators—The Moderna COVID-19 vaccine is likely to make more people sick than COVID-19) originated on Children’s Health Defense and is re-published on our website by ‘contribution’ with attribution to Children’s Health Defense.
Moderna skipped animal testing : https://www.reuters.com/article/us-health-coronavirus-vaccines-insight/as-pressure-for-coronavirus-vaccine-mounts-scientists-debate-risks-of-accelerated-testing-idUSKBN20Y1GZ
The results of Moderna’s phase 1 vaccine trial for COVID-19 were published online in the NEJM : https://pubmed.ncbi.nlm.nih.gov/32663912/
https://nexusnewsfeed.com/article/science-futures/covid-vaccines-will-make-people-more-sick/
https://www.organicconsumers.org/news/how-covid-vaccine-can-destroy-immune-system
https://www.liebertpub.com/doi/pdf/10.1089/088282403763635465
https://blogs.bmj.com/bmj/2020/11/27/covid-19-vaccines-where-are-the-data/
